CagriSema Dosing# CagriSema is a fixed-ratio combination in a single pen injector: Once-weekly subcutaneous injection containing both cagrilintide and semaglutide REDEFINE 1: Dose escalation to the maintenance combination dose over several weeks Dosing ratio: Fixed ratio optimized during the phase 2 program Dosing Comparison Table# Side Effects Comparison# Amycretin Side Effects# In the phase 1b/2a trial published in The Lancet, once-weekly subcutaneous amycretin up to 60 mg had a safety and tolerability profile consistent with GLP-1 and amylin agonists
Common side effects of GLP-1s are gastrointestinal issues, including nausea, vomiting, diarrhea, dehydration, and constipation
Glutathione (90,000mg): A powerful antioxidant that promotes skin whitening and detoxification
In addition to delaying gastric emptying, GLP-1RAs exert direct effects on the central nervous system to suppress appetite and promote weight loss [9, 11]
Keep all pens refrigerated until first use
Serious but rare adverse effects associated with injectable GLP-1 receptor agonists include acute pancreatitis, gallbladder disease (cholecystitis and cholelithiasis), and potential thyroid effects
